Novartis, Cosentyx, secukinumab, polymyalgia rheumatica, PMR, European Commission approval, IL-17A inhibitor, Phase III REPLENISH trial, immunology, inflammatory disease

Basel, Switzerland, October 21, 2026 Novartis has received European Commission approval for Cosentyx® (secukinumab) to treat adults with polymyalgia...